Neutral endopeptidase (EC 3.4.24.11) in cirrhotic liver: a new target to treat portal hypertension?

J Hepatol. 2005 Nov;43(5):791-8. doi: 10.1016/j.jhep.2005.04.017. Epub 2005 Jun 20.

Abstract

Background/aims: In liver cirrhosis atrial natriuretic peptide (ANP) decreases portal vascular resistance and tributary flow. The enzyme neutral endopeptidase (NEP) degrades ANP and bradykinin and generates endothelin-1 from big-endothelin. We determined the effects of NEP inhibition by candoxatrilat on hormonal status, liver function and arterial and portal pressures in rats with CCl4-induced cirrhosis.

Methods: Two groups of seven control rats received 1 ml 5% glucose solution alone or containing 10 mg/kg candoxatrilat; three groups of 10 ascitic cirrhotic rats received placebo, 5 or 10 mg/kg candoxatrilat. NEP protein concentration and immunostaining were analyzed in normal and cirrhotic livers.

Results: In cirrhotic rats 10 mg/kg candoxatrilat significantly increased steady-state indocyanine green clearance (a parameter reflecting liver plasma flow) (P<0.01), decreased portal pressure (P<0.01), had no effect on arterial pressure and plasma renin activity but increased ANP plasma levels (P<0.05) and urinary excretions (P<0.01) of ANP and cGMP. In the cytosol fraction of rat cirrhotic livers a 280% increase in NEP content was found (P<0.01), chiefly localized in desmin-positive myofibroblast-like cells of fibrous septa.

Conclusions: Candoxatrilat has few effects on systemic hemodynamics and hormonal status; its portal hypotensive action depends on effects exerted on intrahepatic vascular resistance.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Arginine Vasopressin / metabolism
  • Atrial Natriuretic Factor / metabolism
  • Blood Pressure / drug effects
  • Blood Pressure / physiology
  • Carbon Tetrachloride / toxicity
  • Cyclic GMP / metabolism
  • Cyclohexanecarboxylic Acids / metabolism
  • Cyclohexanecarboxylic Acids / pharmacology
  • Cyclohexanecarboxylic Acids / therapeutic use
  • Cytokines / metabolism
  • Endothelin-1 / metabolism
  • Humans
  • Hypertension, Portal / drug therapy*
  • Liver / cytology
  • Liver / enzymology
  • Liver Cirrhosis, Experimental / chemically induced
  • Liver Cirrhosis, Experimental / enzymology*
  • Male
  • Neprilysin* / antagonists & inhibitors
  • Neprilysin* / metabolism
  • Portal Vein / drug effects
  • Portal Vein / physiology
  • Protease Inhibitors / metabolism
  • Protease Inhibitors / therapeutic use
  • Rats
  • Rats, Wistar
  • Vascular Resistance / drug effects
  • Vascular Resistance / physiology*

Substances

  • Cyclohexanecarboxylic Acids
  • Cytokines
  • Endothelin-1
  • Protease Inhibitors
  • Arginine Vasopressin
  • candoxatrilat
  • Atrial Natriuretic Factor
  • Carbon Tetrachloride
  • Neprilysin
  • Cyclic GMP